Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
OVID Stock Summary
Top 10 Correlated ETFs
OVID
In the News
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a panel titled “Orphan Epilepsies” at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. ET in Boston, Massachusetts.
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida.
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics (OVID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York.
3 Very Promising Penny Stocks That Are Flying Under the Radar
Warning: while this discussion obviously centers on penny stocks to buy, this subsegment of the market carries astounding risks. While it's difficult to verify, one source has the failure rate of these speculative, low-market capitalization entities as over 90%.
Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.
Ovid Therapeutics: Bullish Outlook Strengthened By Positive 2-Year Open-Label Trial Results
Ovid Therapeutics' TAK-935 has a high potential for positive Phase 3 clinical trial results for both Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). Significant Revenue Potential. The median annual cost of orphan-designated therapy is approximately $218,000. The estimated total addressable market for TAK-935 includes approximately 159,000 patients with DS and LGS across the US, EU, and Japan.
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.23 per share a year ago.
Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OVID Financial details
OVID Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.22 | 3.09 | 0.02 | 0.01 | |
Net income per share | -1.51 | -1.38 | 1.82 | -0.73 | -0.74 | |
Operating cash flow per share | -1.3 | -0.88 | 1.76 | -0.79 | -0.65 | |
Free cash flow per share | -1.31 | -0.89 | 1.75 | -0.81 | -0.65 | |
Cash per share | 1.96 | 1.24 | 2.78 | 3.03 | 1.5 | |
Book value per share | 1.79 | 0.75 | 2.66 | 1.88 | 1.24 | |
Tangible book value per share | 1.77 | 0.74 | 2.66 | 1.88 | 1.24 | |
Share holders equity per share | 1.79 | 0.75 | 2.66 | 1.88 | 1.24 | |
Interest debt per share | 0 | 0 | 0 | 0.2 | 0.44 | |
Market cap | 162.75M | 134.67M | 216.61M | 130.85M | 227.27M | |
Enterprise value | 120.85M | 62.64M | 28.81M | 18.38M | 246.23M | |
P/E ratio | -2.75 | -1.67 | 1.76 | -2.55 | -4.34 | |
Price to sales ratio | 0 | 10.67 | 1.04 | 87.07 | 580.22 | |
POCF ratio | -3.19 | -2.61 | 1.83 | -2.37 | -4.96 | |
PFCF ratio | -3.17 | -2.59 | 1.83 | -2.31 | -4.95 | |
P/B Ratio | 2.32 | 3.09 | 1.21 | 0.99 | 2.59 | |
PTB ratio | 2.32 | 3.09 | 1.21 | 0.99 | 2.59 | |
EV to sales | 0 | 4.96 | 0.14 | 12.23 | 628.63 | |
Enterprise value over EBITDA | -1.97 | -0.77 | 0.23 | -0.33 | -4.27 | |
EV to operating cash flow | -2.37 | -1.21 | 0.24 | -0.33 | -5.38 | |
EV to free cash flow | -2.35 | -1.21 | 0.24 | -0.32 | -5.36 | |
Earnings yield | -0.36 | -0.6 | 0.57 | -0.39 | -0.23 | |
Free cash flow yield | -0.32 | -0.39 | 0.55 | -0.43 | -0.2 | |
Debt to equity | 0 | 0 | 0 | 0.13 | 0.36 | |
Debt to assets | 0 | 0 | 0 | 0.11 | 0.22 | |
Net debt to EBITDA | 0.68 | 0.88 | -1.51 | 2.02 | -0.33 | |
Current ratio | 7.58 | 3.39 | 12.87 | 18.79 | 9.55 | |
Interest coverage | 0 | 0 | 0 | 20.12 | 0 | |
Income quality | 0.85 | 0.64 | 0.97 | 1.02 | 0.87 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 2.43 | 0.18 | 21.58 | 79.36 | |
Research and developement to revenue | 0 | 5.03 | 0.23 | 16.38 | 71.91 | |
Intangibles to total assets | 0.01 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0.03 | 0 | |
Capex to revenue | 0 | -0.03 | 0 | -0.94 | -0.35 | |
Capex to depreciation | -0.96 | -1.27 | -0.8 | -1.03 | -0.09 | |
Stock based compensation to revenue | 0 | 0.6 | 0.02 | 4.36 | 18.6 | |
Graham number | 7.79 | 4.83 | 10.45 | 5.56 | 4.56 | |
ROIC | -0.86 | -1.86 | 0.68 | -0.32 | -0.44 | |
Return on tangible assets | -0.74 | -1.07 | 0.63 | -0.33 | -0.36 | |
Graham Net | 1.7 | 0.68 | 2.56 | 2.7 | 0.7 | |
Working capital | 69.28M | 52.78M | 175.68M | 124.39M | 98.12M | |
Tangible asset value | 69.56M | 43.31M | 179.58M | 132.05M | 87.61M | |
Net current asset value | 68.99M | 42.55M | 175.68M | 108.39M | 53.37M | |
Invested capital | 0 | 0 | 0 | 0.13 | 0.36 | |
Average receivables | 565.57K | 636.45K | 70.88K | 0 | 0 | |
Average payables | 3.51M | 4.35M | 6.29M | 4.54M | 2.83M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 4.1 | 0 | 0 | 0 | |
Days payables outstanding | 4.66K | 0 | 0 | 515.93 | 846.54 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 89 | 0 | 0 | 0 | |
Payables turnover | 0.08 | 0 | 0 | 0.71 | 0.43 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.85 | -1.85 | 0.68 | -0.39 | -0.6 | |
Capex per share | -0.01 | -0.01 | 0 | -0.02 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.16 | 21.66 | -0.18 | -0.16 | -0.22 | |
Operating cash flow per share | -0.13 | -0.17 | -0.17 | -0.14 | -0.17 | |
Free cash flow per share | -0.13 | -0.17 | -0.17 | -0.14 | -0.17 | |
Cash per share | 3.02 | 1.67K | 1.4 | 1.24 | 1.5 | |
Book value per share | 1.88 | 1.72 | 1.61 | 1.44 | 1.24 | |
Tangible book value per share | 1.87 | 1.72 | 1.6 | 1.44 | 1.24 | |
Share holders equity per share | 1.88 | 1.72 | 1.61 | 1.44 | 1.24 | |
Interest debt per share | 0.22 | -10.19 | 0.24 | 0.23 | 0.44 | |
Market cap | 131.08M | 181.36M | 226.11M | 270.06M | 227.61M | |
Enterprise value | 18.61M | -62.07B | 170.82M | 228.92M | 246.57M | |
P/E ratio | -2.86 | 0.03 | -4.56 | -6 | -3.71 | |
Price to sales ratio | 2.83K | 2.74K | 3.01K | 2.48K | 1.61K | |
POCF ratio | -14.29 | -14.97 | -19.32 | -26.87 | -19.11 | |
PFCF ratio | -14.19 | -14.96 | -19.12 | -26.85 | -19.11 | |
P/B Ratio | 0.99 | 1.5 | 2.04 | 2.67 | 2.59 | |
PTB ratio | 0.99 | 1.5 | 2.04 | 2.67 | 2.59 | |
EV to sales | 402.19 | -938.13K | 2.28K | 2.1K | 1.74K | |
Enterprise value over EBITDA | -1.53 | 4.17K | -12.4 | -19.69 | -13.86 | |
EV to operating cash flow | -2.03 | 5.12K | -14.59 | -22.78 | -20.7 | |
EV to free cash flow | -2.01 | 5.12K | -14.45 | -22.76 | -20.7 | |
Earnings yield | -0.09 | 8.4 | -0.05 | -0.04 | -0.07 | |
Free cash flow yield | -0.07 | -0.07 | -0.05 | -0.04 | -0.05 | |
Debt to equity | 0.13 | 6.78 | 0.15 | 0.16 | 0.36 | |
Debt to assets | 0.11 | 5.72 | 0.12 | 0.13 | 0.22 | |
Net debt to EBITDA | 9.24 | 4.18K | 4.01 | 3.54 | -1.07 | |
Current ratio | 18.79 | 17.78 | 10.07 | 10.59 | 9.55 | |
Interest coverage | 11.5 | 0.01 | 0 | 0 | 0 | |
Income quality | 0.8 | 0.91 | 0.94 | 0.89 | 0.78 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 144.2 | 126.11 | 109.97 | 62.45 | 54.32 | |
Research and developement to revenue | 119.82 | 99.98 | 79.98 | 48.94 | 74.46 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0.01 | 0 | 0 | |
Capex to revenue | -1.36 | -0.2 | -1.57 | -0.05 | -0.01 | |
Capex to depreciation | -0.14 | -0.03 | -0.3 | -0.01 | 0 | |
Stock based compensation to revenue | 37.37 | 28.97 | 25.98 | 14.97 | 12.64 | |
Graham number | 2.62 | 28.96 | 2.55 | 2.28 | 2.46 | |
ROIC | -0.07 | 0.97 | -0.1 | -0.09 | -0.14 | |
Return on tangible assets | -0.07 | 10.64 | -0.09 | -0.09 | -0.11 | |
Graham Net | 2.7 | 1.67K | 1.03 | 0.9 | 0.7 | |
Working capital | 124.39M | 112.8B | 92.03M | 83.05M | 98.12M | |
Tangible asset value | 132.05M | 120.76M | 110.44M | 101.07M | 87.61M | |
Net current asset value | 108.39M | 119.5B | 76.64M | 67.98M | 53.37M | |
Invested capital | 0.13 | 6.78 | 0.15 | 0.16 | 0.36 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.49M | 916.72M | 917.63M | 2.49M | 2.46M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 399.5 | -2.49K | -4.52 | -1.01 | 830.27 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.23 | -0.04 | -19.91 | -89.48 | 0.11 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.09 | 12.59 | -0.11 | -0.11 | -0.17 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
OVID Frequently Asked Questions
What is Ovid Therapeutics Inc. stock symbol ?
Ovid Therapeutics Inc. is a US stock , located in New york of Ny and trading under the symbol OVID
What is Ovid Therapeutics Inc. stock quote today ?
Ovid Therapeutics Inc. stock price is $3.08 today.
Is Ovid Therapeutics Inc. stock public?
Yes, Ovid Therapeutics Inc. is a publicly traded company.